Novartis ADR Forecast, price target & analysts
Novartis ADR Target price 2026 - Analyst rating & recommendation
Novartis ADR Classifications & Recommendation
Novartis ADR Price Target
| Target Price | $158.60 |
| Price | $140.92 |
| Potential |
12.55%
register free of charge
|
| Number of Estimates | 27 |
|
27 Analysts have issued a price target Novartis ADR 2027 .
The average Novartis ADR target price is $158.60.
This is
12.55%
register free of charge
$190.74
35.35%
register free of charge
$125.98
10.60%
register free of charge
|
|
| A rating was issued by 34 analysts: 16 Analysts recommend Novartis ADR to buy, 14 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Novartis ADR stock has an average upside potential 2027 of
12.55%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 56.33 | 58.20 |
| 8.91% | 3.32% | |
| EBITDA Margin | 33.67% | 41.05% |
| 5.37% | 21.91% | |
| Net Margin | 24.83% | 29.05% |
| 7.53% | 17.02% |
29 Analysts have issued a sales forecast Novartis ADR 2026 . The average Novartis ADR sales estimate is
This results in the following potential growth metrics:
24 Analysts have issued an Novartis ADR EBITDA forecast 2026. The average Novartis ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
28 Novartis ADR Analysts have issued a net profit forecast 2026. The average Novartis ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 7.15 | 8.90 |
| 21.81% | 24.48% | |
| P/E | 15.59 | |
| EV/Sales | 5.05 |
28 Analysts have issued a Novartis ADR forecast for earnings per share. The average Novartis ADR EPS is
This results in the following potential growth metrics and future valuations:
Current Novartis ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| TD COWEN |
Locked
➜
Locked
|
Locked | Jul 14 2026 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| ROTHSCHILD & CO REDBURN |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| ARGUS RESEARCH CORPORATION |
Locked
➜
Locked
|
Locked | Jul 09 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Jun 30 2026 |
| INTESA SANPAOLO EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Jun 30 2026 |
| GUGGENHEIM SECURITIES LLC |
Locked
➜
Locked
|
Locked | Jun 28 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
TD COWEN:
Locked
➜
Locked
|
Jul 14 2026 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
ROTHSCHILD & CO REDBURN:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
ARGUS RESEARCH CORPORATION:
Locked
➜
Locked
|
Jul 09 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Jun 30 2026 |
|
Locked
INTESA SANPAOLO EQUITY RESEARCH:
Locked
➜
Locked
|
Jun 30 2026 |
|
Locked
GUGGENHEIM SECURITIES LLC:
Locked
➜
Locked
|
Jun 28 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
